A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- Biological: PlaceboBiological: AK101 SCBiological: AK101 IV/AK101 SCBiological: AK101 IV
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Akeso
- Target Recruit Count
- 34
- Registration Number
- NCT06281704
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
- Conditions
- Higher-risk Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Akeso
- Target Recruit Count
- 90
- Registration Number
- NCT06196203
- Locations
- 🇺🇸
Mid Florida Hematology and Oncology Center, Orange City, Florida, United States
🇺🇸UCLA Ronald Reagan Medical Center, Los Angeles, California, United States
🇺🇸American Oncology Partners, PA (The Center for Cancer and Blood Disorders-Bethesda), Bethesda, Maryland, United States
A Study of AK131 in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Akeso
- Target Recruit Count
- 130
- Registration Number
- NCT06166888
- Locations
- 🇨🇳
Jinming Yu, Jinan, Shandong, China
A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Akeso
- Target Recruit Count
- 72
- Registration Number
- NCT06166472
- Locations
- 🇨🇳
Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Sun Yat-Sen University Cancer Center, Guangzhou, China, Guangzhou, Guangdong, China
🇨🇳The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Akeso
- Target Recruit Count
- 180
- Registration Number
- NCT06092762
- Locations
- 🇨🇳
The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳People Hospital of Xingtai, Xingtai, Hebei, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Akeso
- Target Recruit Count
- 351
- Registration Number
- NCT06066125
- Locations
- 🇨🇳
Dermatology Hospital of China Union Medical University, Nanjing, Jiangsu, China
🇨🇳Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳The first affiliated hospital of Bengbu Medical College, Bengbu, Anhui, China
To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Akeso
- Target Recruit Count
- 454
- Registration Number
- NCT06061471
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳Affiliated Hospital of Chengde Medical University, Chengde, Hebei, China
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Akeso
- Target Recruit Count
- 427
- Registration Number
- NCT06035354
- Locations
- 🇨🇳
AkesoBio Investigative Site 2037, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳AkesoBio Investigative Site 2036, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳AkesoBio Investigative Site 1001, Peking University People's Hospital, Beijing, Beijing, China
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
- Conditions
- Locally Advanced or Metastatic NSCLC
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Akeso
- Target Recruit Count
- 642
- Registration Number
- NCT05990127
- Locations
- 🇨🇳
The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
🇨🇳The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳Cancer hospital, Chinese academy of medical sciences and Peking union medical college, Beijing, Beijing, China
Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
- Conditions
- Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Akeso
- Target Recruit Count
- 90
- Registration Number
- NCT05960955
- Locations
- 🇨🇳
Tianjin Provincial Tumor Hospital, Tianjin, China